IL326113A - Methods of using factor b inhibitors - Google Patents
Methods of using factor b inhibitorsInfo
- Publication number
- IL326113A IL326113A IL326113A IL32611326A IL326113A IL 326113 A IL326113 A IL 326113A IL 326113 A IL326113 A IL 326113A IL 32611326 A IL32611326 A IL 32611326A IL 326113 A IL326113 A IL 326113A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- factor
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363578694P | 2023-08-25 | 2023-08-25 | |
| US202463668430P | 2024-07-08 | 2024-07-08 | |
| PCT/IB2024/058205 WO2025046421A1 (en) | 2023-08-25 | 2024-08-23 | Methods of using factor b inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL326113A true IL326113A (en) | 2026-03-01 |
Family
ID=93061572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL326113A IL326113A (en) | 2023-08-25 | 2024-08-23 | Methods of using factor b inhibitors |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN121712505A (en) |
| AU (1) | AU2024332373A1 (en) |
| IL (1) | IL326113A (en) |
| TW (1) | TW202508580A (en) |
| WO (1) | WO2025046421A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3425B1 (en) | 2013-07-15 | 2019-10-20 | Novartis Ag | Piperidinyl indole derivatives and their use as complement factor b inhibitors |
| TW202504893A (en) | 2020-05-18 | 2025-02-01 | 瑞士商諾華公司 | Crystalline form of lnp023 |
| CN114057758A (en) * | 2020-08-07 | 2022-02-18 | 上海美悦生物科技发展有限公司 | Complement factor B inhibitor and pharmaceutical composition, preparation method and application thereof |
-
2024
- 2024-08-23 CN CN202480052153.2A patent/CN121712505A/en active Pending
- 2024-08-23 IL IL326113A patent/IL326113A/en unknown
- 2024-08-23 WO PCT/IB2024/058205 patent/WO2025046421A1/en active Pending
- 2024-08-23 TW TW113131802A patent/TW202508580A/en unknown
- 2024-08-23 AU AU2024332373A patent/AU2024332373A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN121712505A (en) | 2026-03-20 |
| AU2024332373A1 (en) | 2025-10-23 |
| TW202508580A (en) | 2025-03-01 |
| WO2025046421A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL325340A (en) | Kras inhibitors | |
| ZA202212146B (en) | Inhibitors of nek7 kinase | |
| IL320739A (en) | Inhibitors of rock2 | |
| IL314049A (en) | Parp7 inhibitors | |
| IL287293A (en) | Rna editing inhibitors and methods of use | |
| EP4452967A4 (en) | Inhibitors of sars-cov-2 | |
| IL316616A (en) | Inhibitors of rock2 | |
| IL316204A (en) | Methods of administering myosin inhibitors | |
| IL313548A (en) | Inhibitors of met kinase | |
| HUE072981T2 (en) | Azaquinolines as inhibitors of cd38 | |
| IL312466A (en) | Pi3k-alpha inhibitors and methods of making and using the same | |
| LT4192814T (en) | Inhibitors of transglutaminases | |
| IL317768A (en) | Methods of making modified btk inhibitors | |
| IL315980A (en) | Egfr inhibitors | |
| SI4192813T1 (en) | Inhibitors of transglutaminases | |
| IL326113A (en) | Methods of using factor b inhibitors | |
| SI4192812T1 (en) | Inhibitors of transglutaminases | |
| GB202203181D0 (en) | Inhibitors of elF4A | |
| CA3294294A1 (en) | Methods of using factor b inhibitors | |
| CA3283726A1 (en) | Methods of using factor b inhibitors | |
| HK40128702A (en) | Methods of using factor b inhibitors | |
| GB202107612D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL320661A (en) | Solid forms of complement factor b inhibitors | |
| IL320219A (en) | Inhibitors | |
| CA3289184A1 (en) | Heteroarylindole inhibitors of apol-1 |